A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM

Liver Metastases Clinical Trial

Official title:

Systemic Chemotherapy With Irinotecan Plus Hepatic Arterial Infusion With Floxuridine and Oxaliplatin in Patients With Initially Unresectable Colorectal Liver Metastasis: A Prospective Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03493061
• Other study ID #: HAI-CRCLM
• Status: Completed
• Phase: Phase 2
• Start date: February 1, 2018
• Est. completion date: December 30, 2022

Study information

• Verified date: February 2023
• Source: Sun Yat-sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer Liver Metastasis. The patients will be treated with systemic chemotherapy With irinotecan plus hepatic arterial infusion With floxuridine and oxaliplatin

Description:

Recent studies and our experience have proved the efficacy and safety of systemic chemotherapy combined with hepatic arterial infusion (HAI) with floxuridine and dexamethasone in patients with initially unresectable colorectal liver metastasis. Hepatic arterial infusion oxaliplatin trials have been done with oxaliplatin alone and in combination with irinotecan, 5-FU/LV, and mitomycin-C and have showed that Hepatic arterial infusion oxaliplatin could increase response rate and resection rate for colorectal liver metastasis. Therefore, we designed this study to determine whether systemic chemotherapy With irinotecan plus hepatic arterial infusion With floxuridine and oxaliplatin can increase the complete resection rate (R0) and improve the overall survival in patients with initially unresectable colorectal liver metastasis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 30, 2022
• Est. primary completion date: December 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age: 18-70 years old

• Histologically confirmed colorectal adenocarcinoma

• Radiologically or pathologically confirmed diagnosis of colorectal liver metastasis

• Initially unresectable colorectal liver metastasis confirmed by the multidisciplinary team (MDT)

• With no prior treatment for liver metastasis, including chemotherapy, operation, radiotherapy, transcatheter hepatic arterial chemoembolization (TACE) and targeted therapy

• Without extra-hepatic metastasis confirmed by CT, MRI or PET/CT (if necessary) scanning

• With adequate bone marrow function: platelets = 90 x 109/L; white blood cells = 3×109/L; absolute neutrophil count (ANC) = 1.5 x 109/L Serum bilirubin = 1.5 x ULN, AST and ALT = 5 x ULN

• Patient has no ascites and with adequate blood coagulation function, albumin = 35 g/L

• Grade A level of Child-Push Liver Function

• Creatinine = 1× ULN, or Calculated Creatinine Clearance >50ml/min (Cockcroft-Gault Equation)

• ECOG performance status of 0-2

• Life expectancy = 3 months

• Not appropriate for anti-EGFR or any other targeted therapy (with KRAS mutation or could not afford it)

• Patients have provided a signed Informed Consent Form

• With good compliance

Exclusion Criteria:

• With any extra-hepatic metastasis and/or primary tumor recurrence

• Severe arterial embolism or ascites

• With hemorrhagic tendency or coagulation disorders

• Hypertensive crisis or hypertensive encephalopathy

• Severe and uncontrolled systemic complications such as infections or diabetes.

• Serious cardiovascular diseases such as cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), uncontrolled hypertension even with appropriate drug intervention, unstable angina pectoris, congestive heart failure (NYHA 2-4 degree), arrhythmia that needs medication intervention

• Patient who has suffered from central nervous system diseases such as primary brain tumor, uncontrolled epilepsy even with standard treatment, any brain metastasis or stroke

• Patient who has a concurrent malignancy or has a malignancy within 5 years before study enrollment, (with the exception of radically resected skin basal cell carcinoma or cervical carcinoma in situ)

• Patient who has received any investigational antineoplastic agent within 28 days before the enrollment

• Any residual toxicity from prior chemotherapy (with the exception of alopecia), such as grade 2 or more sensory peripheral neuropathy (NCI CTC v3.0), oxaliplatin-based regimen will not be considered

• Patient who is allergic to oxaliplatin, leucovorin, 5-Fluorouracil, floxuridine or dexamethasone

• Pregnant or lactating women

• Patient who does not use or refuses to take any appropriate contraceptive measures (intrauterine contraceptive ring, barrier contraception combined with spermicidal gel or sterilization operation), including women of childbearing age (within 2 years after the last menstrual period) and men who are with possible fertility

• Unable or unwilling to comply with the research plan

• The existence of any other disease, dysfunction caused by metastatic lesions, or suspicious disease found on the regular examination, which indicating contraindications to the use of study drugs or may bring high risks of treatment related complications

Related Conditions & MeSH terms

• Colo-rectal Cancer
• Liver Metastases
• Neoplasm Metastasis

Intervention

Drug:
• Irinotecan
Irinotecan 150 mg/m2 IV over 90 minutes on Day 1, 15
• Oxaliplatin
Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
• Floxuridine
0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.

Locations

Country	Name	City	State
China	Sun Yat-sen University Cancer Center	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete resection rates (R0 resection rates)	defined as no macroscopic or microscopic residual tumor	Up to 2-4 months